Compugen establishs Advisory Board to guide pipeline development

Compugen (CGEN +5.4%) moves up today after saying it's established a Scientific Advisory Board to guide its pipeline development.

The board will focus on advancing activities in the fields ofimmunology and oncology, including its early stage pipeline of therapeutic proteins and monoclonal antibodies.

The members include four renowned translational scientists and clinicians in oncology and immunology: Charles Drake, MD, PhD, Associate Professor of Oncology, Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain McInnes, MD, PhD, Director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow; Antoni Ribas, MD, PhD, Professor at the Department of Medicine, Hematology/Oncology, UCLA; and Howard Soule, PhD, EVP and Chief Science Officer, Prostate Cancer Foundation.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs